Turkish Version of the Parent-Reported Drug Hypersensitivity Quality of Life Questionnaire
NCT ID: NCT07069439
Last Updated: 2025-12-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
74 participants
OBSERVATIONAL
2025-08-01
2025-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Knowledge, Attitudes and Practices of Healthcare Workers on Drug Hypersensitivity Reactions in Children
NCT04252326
Effect of Rational Drug Education on the Attitudes of Parents of Hospitalized Children
NCT06495320
Validation of Turkish Versions Child- and Parent-Rated Scales of Food Allergy Anxiety
NCT07019389
Rational Drug Use Education Parental Attitudes
NCT05331898
Development and Validation of the Air Quality Awareness Scale (AQAS) for Parents
NCT07283250
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Caregiver Cohort
This cohort will consist of adult caregivers (parents or legal guardians) of children under 18 years of age with a documented history of drug hypersensitivity. Participants will complete the Turkish version of the Parent-reported Drug Hypersensitivity Quality of Life Questionnaire (P-DrHy-Q) to evaluate its psychometric properties, including internal consistency and test-retest reliability.
Turkish Version of the P-DrHy-Q
Participants will complete the Turkish-translated version of the Parent-reported Drug Hypersensitivity Quality of Life Questionnaire (P-DrHy-Q), which includes 12 items assessing psychosocial burden in two domains: mental health and social activity. A subgroup of participants (n ≈ 20) will complete the same questionnaire again after 14 days to assess test-retest reliability
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Turkish Version of the P-DrHy-Q
Participants will complete the Turkish-translated version of the Parent-reported Drug Hypersensitivity Quality of Life Questionnaire (P-DrHy-Q), which includes 12 items assessing psychosocial burden in two domains: mental health and social activity. A subgroup of participants (n ≈ 20) will complete the same questionnaire again after 14 days to assess test-retest reliability
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Primary caregiver of a child under the age of 18
* Child must have a documented history of drug hypersensitivity
* Fluent in written and spoken Turkish
* Willingness to participate and provide written informed consent
* Availability to complete both baseline and follow-up questionnaire within the designated time frame
Exclusion Criteria
* Inability to read or write in Turkish
* Child currently experiencing an acute drug hypersensitivity reaction
* Previous participation in the pilot testing phase of this validation study
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hilal Gungor
Medical Doctor, Pediatric Immunology and Allergy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-300613
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.